Hormonal contraception and risk of STIs and bacterial vaginosis in South African adolescents: secondary analysis of a randomised trial

Sex Transm Infect. 2021 Mar;97(2):112-117. doi: 10.1136/sextrans-2020-054483. Epub 2020 Sep 28.

Abstract

Objectives: Young women in sub-Saharan Africa are at high risk of STIs and unintended pregnancies, yet hormonal contraceptive (HC) use may affect STI risk. We compared the influence of three HCs on the incidence and prevalence of STIs and bacterial vaginosis (BV) in South African adolescents.

Methods: One hundred and thirty adolescents between 15 and 19 years were randomised to the injectable norethisterone enanthate (Net-En), combined oral contraceptives (COC) (Triphasil or Nordette) or a combined contraceptive vaginal ring (CCVR; NuvaRing) for 16 weeks (clinicaltrials.gov/NCT02404038). Vaginal samples were collected at baseline and 16 weeks post contraceptive initiation for STI and BV testing.

Results: In an intention-to-treat analysis, no significant differences in BV prevalence were found between study arms. The overall incidence of any STI at follow-up was high: 16.2% in the COC arm; 25.7% in the Net-En arm; and 37.1% in the CCVR arm. The incidence rate (IR) of any STI was similar between Net-En (IR 0.74 (95% CI 0.34 to 1.41)) and the oestrogen-containing contraceptives (IR 0.78 (95% CI 0.47 to 1.22)). A lower IR of Chlamydia trachomatis (incidence rate ratio (IRR) 0.68 (95% CI 0.19 to 1.99)) and Neisseria gonorrhoeae (IRR 0.25 (95% CI 0.01 to 1.35)) but a higher IR of Mycoplasma genitalium (IRR 16.0 (95% CI 2.96 to 400)), was observed in the Net-En arm compared with the oestrogen-containing contraceptives, although the overall incidence of M. genitalium was low (4.7%). In an exploratory analysis, the risk of any STI and N. gonorrhoeae was lower in the COC arm compared with CCVR. A per-protocol analysis yielded similar results.

Conclusion: Our results suggest that use of Net-En may be associated with increased risk of M. genitalium compared with oestrogen-containing contraceptives but not with overall STI risk. COC use may decrease STI risk relative to CCVR.

Keywords: adolescent; bacterial vaginosis; clinical trials; hormonal contraception.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Bacteria / classification
  • Bacteria / isolation & purification
  • Contraceptive Devices, Female
  • Contraceptives, Oral, Combined / administration & dosage
  • Contraceptives, Oral, Combined / adverse effects
  • Cross-Over Studies
  • Female
  • Hormonal Contraception / adverse effects
  • Hormonal Contraception / methods*
  • Humans
  • Incidence
  • Intention to Treat Analysis
  • Norethindrone / administration & dosage
  • Norethindrone / adverse effects
  • Norethindrone / analogs & derivatives
  • Risk
  • Sexually Transmitted Diseases / diagnosis
  • Sexually Transmitted Diseases / drug therapy
  • Sexually Transmitted Diseases / epidemiology*
  • Sexually Transmitted Diseases / microbiology
  • South Africa / epidemiology
  • Species Specificity
  • Vagina / microbiology
  • Vaginosis, Bacterial / diagnosis
  • Vaginosis, Bacterial / drug therapy
  • Vaginosis, Bacterial / epidemiology*
  • Vaginosis, Bacterial / microbiology
  • Young Adult

Substances

  • Contraceptives, Oral, Combined
  • norethindrone enanthate
  • Norethindrone

Associated data

  • ClinicalTrials.gov/NCT02404038